FEDERAL AND STATE LEGISLATION TRACKING
Federal Legislation & Government Insights Tracking and Coverage
Gain access to reports and strategic insights written by our team of legal analysts, clinical pharmacists, and senior researchers covering legislation and government-related lawsuits that may have an impact on drug pricing, patient access, drug reimbursement, and intellectual property covering drug products.
Focused on high-impact bills, rules, regulations, executive orders, and government-related lawsuits, our Legislation & Government Insights will help you understand their potential effects on the marketplace and healthcare stakeholders.
In addition to comprehensive reports and real-time email updates following legislation moving through the House of Representatives or Senate and being challenged in court, our High-Impact Legislation & Government Insights Tracker allows you to easily monitor statuses, outcomes, and important details of each ongoing situation.
State Legislation & Government Insights Tracking and Coverage
Track current and proposed state legislation impacting payer coverage, drug pricing, utilization management, pharmacy benefit managers, pharmacy practices, and more with access to state-by-state topic coverage, data visualizations, source information, and consults with our expert team.
Explore Recent Reports
August 2026
Medicare Part D Plan Availability and Enrollment Trends Following the 2025 Benefit Redesign
IPD Analytics has released a new report, “Medicare Part D Plan Availability and Enrollment Trends Following the 2025 Benefit Redesign.” This report examines how the 2025 benefit redesign has already begun reshaping the Part D landscape, including changes in plan availability, sponsor market participation, and enrollment movement as sponsors reassess PDP and MAPD offerings in response to heightened financial risk.
May 2026
Most-Favored-Nation Drug Pricing Update: Regeneron Agreement and Observations on New Drug Pricing
IPD Analytics has released a new report, “Most-Favored-Nation Drug Pricing Update: Regeneron Agreement and Observations on New Drug Pricing.” On April 23, 2026, Regeneron reached a “most-favored-nation” (MFN) pricing agreement with the Trump administration, as the last among 17 manufacturers that the White House says represent 86% of the branded drug market.